Study of Motor Slowing in Parkinson's Disease by a Computerized Mental Chronometry Paradigm

NCT02814201 | Completed

• 1 other identifier: PI10-DR-DURU
• Study Type: observational
• Target: 55
• Locations: 1 country
• Sites: 1

Brief Summary

Action slowing has been demonstrated in many diseases. Parkinson's disease (PD) and Huntington's disease (HD) are two neurodegenerative diseases affecting the basal ganglia, particularly the medial globus pallidus, and the clinical expression of these two diseases is characterized by a combination of motor and cognitive disorders, but with two opposing patterns of dysfunction. Action slowing has been demonstrated in both of these diseases and has been extensively studied in Parkinson's disease, suggesting a perceptive-cognitive origin. Far fewer studies have been conducted in Huntington's disease. However, all of these studies were performed with different methodologies in small cohorts and the value of the proposed study is to use a validated and standardized computerized mental chronometry paradigm, providing a better understanding of the mechanisms of action slowing in these two diseases and to more clearly define a disease-specific profile.

Conditions

Parkinson Disease; Huntington Disease

Keywords

Motor slowing; Computerized mental chronometry paradigm

Outcome Measures

Primary Outcomes (1)

• SRT

  simple reaction time ( SRT) defined as the fastest response time to a target stimulus ( phase "worst -off" at the Parkinson's patient )

  Day 0

Study Arms (4)

Parkinson best-On

two hours after taking two tablets of 125 mg dispersible Modopar®

Behavioral: SRT

Parkinson worst-off

after a drug withdrawal period ( morning fasting all dopaminergic treatment since the day before midnight)

Behavioral: SRT

Huntington

Behavioral: SRT

Control

Data collected from the existing database

Behavioral: SRT

Interventions

SRT BEHAVIORAL

simple reaction time ( SRT) defined as the fastest response time to a target stimulus ( phase "worst -off" at the Parkinson's patient )

Control; Huntington; Parkinson best-On; Parkinson worst-off

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)
• Sampling Method: Non-Probability Sample

Study Population

Patients with Hoehn and Yahr stage 1 to 3 Parkinson's disease and patients with Shoulson stage I and II Huntington's disease, in whom admission to the Neurology ward is scheduled in the context of their follow-up, comprising a neuropsychological assessment (together with an acute L-dopa administration test for Parkinsonian patients) will be included

You may qualify if:

• Agreeing to participate in the study
• French mother tongue
• MMSE \> 20/30
• Specific to the MP and MH:
• Parkinson's disease:
• defined by the criteria of the UKPDSBB
• stage 1 , 2 or 3 Hoehn and Yahr (ON)
• age of onset of the disease known
• brain MRI performed during follow-up
• Huntington disease :
• genetically defined (CAG \> 35)
• weaning neuroleptic ( Tercian® and Solian® : 2 days; Haldol® : 5 days ; Tiapridal® and Xenazine : 1 day ; Zyprexa® : 4 days)
• Early stage : Fahn and Shoulson I and II is a CFT score between 7 and 13

You may not qualify if:

• Illiteracy, writing or reading difficulties
• Visual perceptual auditory deficit or preventing reading, drawing, writing or understanding instructions
• Visual hallucinations
• Significant history may sound on cognition (unbalanced thyroid dysfunction, ischemic heart disease or embolic unstabilized or symptomatic, progressive neoplasia, chronic alcoholism weaned or not)
• Current or previous neurological diseases other than MH or MP: ischemic cerebral vascular accident or bleeding, head injuries (loss of higher knowledge in 15 minutes), epilepsy requiring treatment.
• Psychiatric disorders depression unless treated (stable treatment for 1 month)
• Psychotropic treatment (except anxiolytic, antidepressant steady since 1 month)
• Inability to achieve an autonomous operation without technical assistance over a distance of 20 meters.
• Inability to stand without technical assistance for 30 seconds.

Sponsors & Collaborators

• Centre Hospitalier Universitaire, Amiens: lead

Study Sites (1)

CHU Amiens

Amiens, 80054, France

Location

MeSH Terms

Conditions

Parkinson Disease; Huntington Disease

Condition Hierarchy (Ancestors)

Parkinsonian Disorders; Basal Ganglia Diseases; Brain Diseases; Central Nervous System Diseases; Nervous System Diseases; Movement Disorders; Synucleinopathies; Neurodegenerative Diseases; Dementia; Chorea; Dyskinesias; Heredodegenerative Disorders, Nervous System; Genetic Diseases, Inborn; Congenital, Hereditary, and Neonatal Diseases and Abnormalities; Cognition Disorders; Neurocognitive Disorders; Mental Disorders

Study Officials

• Pierre KRYSTKOWIAK, MD, PhD

  CHU Amiens

  PRINCIPAL INVESTIGATOR

Study Design

• Study Type: observational
• Observational Model: CASE CONTROL
• Time Perspective: PROSPECTIVE
• Sponsor Type: OTHER
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: June 23, 2016
• First Posted: June 27, 2016
• Study Start: July 1, 2011
• Primary Completion: November 1, 2016
• Study Completion: November 1, 2016
• Last Updated: December 5, 2016

Record last verified: 2016-12

Locations

FR (1)